Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-17T16:35:58.426Z Has data issue: false hasContentIssue false
  • English
  • Français

Muscarinic Binding and Choline Acetyltransferase in Postmortem Brains of Demented Patients

Published online by Cambridge University Press:  18 September 2015

Steven B. Waller ,
Melvyn J. Ball ,
Mark A. Reynolds  and
Edythe D. London
Steven B. Waller*
Affiliation:
Department of Physiology and Pharmacology, University of South Dakota School of Medicine, Vermillion, South Dakota
Melvyn J. Ball
Affiliation:
Department of Pathology, University of Western Ontario, London, Ontario
Mark A. Reynolds
Affiliation:
Baltimore College of Dental Surgery, Dental School, University of Maryland, Baltimore, Maryland
Edythe D. London
Affiliation:
Neuropharmacology Laboratory, Addiction Research Center, National Institute on Drug Abuse, Baltimore, Maryland
*
Department of Physiology and Pharmacology, University of South Dakota School of Medicine, Vermillion, SD 57069 USA
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Postmortem human brain samples were taken from non-neurological controls as well as demented subjects who died with Alzheimer's disease (AD), multi-infarct dementia (MID), or a combination of AD and MID dementia (MIXED). Choline acetyltransferase (Ch AT) activity was measured radiometrically using [ 1 -l4C]acetyl-coenzyme A as the substrate, muscarinic binding was assayed with [3H]quinuclidinyl benzilate, and the proportion of binding associated with high affinity agonist sites was measured by carbamylcholine displacement of the radioligand.

Relative to control, ChAT activity was significantly reduced (p ≤0.01) in samples taken from the temporal, frontal, and hippocampal areas of demented patients. A small elevation in Bmax was noted in the hippocampal endplate (p ≤0.01) (AD vs. control) and the H1-subiculum region (p ≤0.05) (AD vs. all other groups). In addition, the percentage of binding associated with high affinity agonist sites was greater in the frontal cortex of AD and MID samples (p≤0.05), compared with MIXED and control, and in the temporal cortex of the AD group compared with all other groups (p≤0.05). The results suggest a regionally specific upregulation of cerebral muscarinic receptors in dementia, especially in AD.

Type
Biochemical Studies
Information
Canadian Journal of Neurological Sciences , Volume 13 , Issue S4 , November 1986 , pp. 528 - 532
Copyright
Copyright © Canadian Neurological Sciences Federation 1986

References

1.Terry, R, Davies, P.Dementia of the Alzheimer-type. Ann Rev Neurosci 1980; 3: 77–95.CrossRefGoogle ScholarPubMed
2.Gottfries, C-G, Adolfsson, R, Aquilonius, S-M, et al. Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging 1983; 4: 261–271.CrossRefGoogle ScholarPubMed
3.Hardy, J, Adolfsson, R, Alafuzoff, I, et al. Transmitters deficits in Alzheimer’s disease. Neurochem Int 1985; 7: 545–563.CrossRefGoogle ScholarPubMed
4.Ball, M, Merskey, H, Fisman, M, et al. Hippocampal morphometry in Alzheimer dementia: Implications for neurochemical hypotheses. In: Katzman, R ed. Banbury Report 15: BiologicalAspeas ofAlzheimer’s Disease. Cold Spring Harbor, Maine: Cold Spring Harbor Laboratories, 1983; 45–57.Google Scholar
5.Bull, G, Oderfeld-Nowak, B. Standardization of a radiometric assay of choline acetyltransferase and a study of the activation of the enzyme in rabbit brain. J Neurochem 1971; 19: 1421–1428.Google Scholar
6.McKinney, M and Coyle, J.Regulation of neocortical muscarinic receptors: Effects of drug treatments and lesions. J Neurosci 1982;2:97–105.CrossRefGoogle ScholarPubMed
7.Waller, S, Ball, M, Reynolds, M, et al. Muscarinic binding in postmor- tem brains of demented patients. Neurobiol Aging 1985; (submitted).Google Scholar
8.Lowry, O, Rosebrough, N, Farr, A, et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265–275.CrossRefGoogle ScholarPubMed
9.Nie, N, Hull, C, Jenkins, J, et al. Statistical Package for the Social Sciences. New York: McGraw-Hill, 1975.Google Scholar
10.Keppel, G.Design and Analysis: A Researcher’s Handbook. Engle- wood Cliffs, California: Prentice-Hall, 1973. Lang, W and Henke, H. Cholinergic receptor binding and autoradiography in brains of non-neurological and senile dementia of the Alzheimer-type patients. Brain Res 1983; 267: 271–280.Google Scholar
11.Perry, E, Tomlinson, B, Blessed, G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978; 2: 1457–59.CrossRefGoogle ScholarPubMed
12.Bowen, D, White, P, Spillane, J,et al. Accelerated aging or selective neuron loss as an important cause of dementia. Lancet 1979; 1: 11–14.Google ScholarPubMed
13.Wilcock, G, Esiri, M, Bowen, D, et al. Alzheimer’s disease: Correla- tion of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 1982;57:407–417.CrossRefGoogle Scholar
14.Davies, P, Verth, A.Regional distribution of muscarinic acetylcho- line receptor in normal and Alzheimer’s type dementia brains. Brain Res 1978; 138: 385–392.CrossRefGoogle Scholar
15.Jenni-Eiermann, S, von Hahn, HP, Honeggar, CG, et al. Studies on neurotransmitter binding in senile dementia: Comparison of Alzheimer’s and Mixed Vascular-Alzheimer’s dementias. Gerontology 1984; 30: 350–358.CrossRefGoogle ScholarPubMed
16.Nordberg, A, Larsson, C, Adolsfsson, R, et al. Muscarinic receptor compensation in hippocampus of Alzheimer patients. J Neural Transmission 1983; 56: 13–19.CrossRefGoogle ScholarPubMed
17.Perry, E.The cholinergic system in old age and Alzheimer’s disease. Age and Ageing 1980; 9: 1–8.CrossRefGoogle ScholarPubMed
18.Caulfield, M, Straughan, D, Cross, A, et al. Cortical muscarinic receptor subtypes and Alzheimer’s disease. Lancet 1982; 1: 1277.CrossRefGoogle Scholar
19.Palacios, J.Autoradiographic localization of muscarinic choliner- gic receptors in the hippocampus of patients with senile dementia. Brain Res 1982; 243: 173–175.CrossRefGoogle Scholar
20.Lang, W, Henke, H.Cholinergic receptor binding and autoradiogra- phy in brains of non-neurological and senile dementia of the Alzheimer-type patients. Brain Res 1983; 267: 271–280.CrossRefGoogle Scholar
21.Reisine, T, Yamamura, H, Bird, E, et al. Pre- and postsynaptic neurochemical alterations in Alzheimer’s disease. Brain Res 1978; 159: 477–481.CrossRefGoogle ScholarPubMed
22.Perry, E, Perry, R.The cholinergic system in Alzheimer’s disease. In: Roberts, P. ed. Biochemistry of Dementia New York: John Wiley and Sons, 1980; 135–183.Google Scholar
23.Rinne, J, Laakso, K, Lonnberg, P, et al. Brain muscarinic receptors in senile dementia. Brain Res 1985; 336: 19–25.CrossRefGoogle ScholarPubMed
24.Rinne, J, Rinne, J, Laakso, K, et al. Reduction in muscarinic recep- tor binding in limbic areas of Alzheimer brain. J Neurol Neurosurg Psychiatry 1984; 47: 651–652.CrossRefGoogle Scholar
25.Mash, D, Flynn, D and Potter, L . Loss of M2 muscarinic receptors in the cerebral cortex in Alzheimer’s disease and experimental cholinergic denervation. Science 1985; 228: 1115–1117.CrossRefGoogle ScholarPubMed
26.Ben-Barak, J, Dudai, Y.Scopalamine induces an increase in musca- rinic receptor level in rat hippocampus. Brain Res 1980; 193: 309–313.CrossRefGoogle Scholar
27.Simon, R, Klein, W.Cholinergic activity regulates muscarinic recep- tors in nervous system cultures. Proc Natl Acad Sci USA 1979; 76: 4141–4145.CrossRefGoogle Scholar
28.Burt, D.Muscarinic receptor binding in rat sympathetic ganglia is unaffected by denervation. Brain Res 1978; 143: 573–579.CrossRefGoogle ScholarPubMed
29.Sachs, D, Kloog, Y, Korczyn, A, et al. Denervation supersensivity and muscarinic receptors in the cat iris. Biochem Pharmacol 1978; 28: 1513–1518.CrossRefGoogle Scholar
30.Reisine, T, Fields, J, Yamamura, H, et al. Neurotransmitter receptor alterations in Parkinson’s disease. Life Sci 1977; 21: 335–344.CrossRefGoogle ScholarPubMed
31.Ruberg, M, Ploska, A, Javoy-Agid, F, et al. Muscarinic binding and choline acetyltransferase activity in Parkinsonian subjects with reference to dementia. Brain Res 1982; 232: 129–139.CrossRefGoogle ScholarPubMed
32.Hyman, BT, Van Hoesen, GW, Damasio, AR, et al. Alzhemier’s Disease: Cell-specific pathology isolates the hippocampal formation. Science 1984; 225: 1168–1170.CrossRefGoogle Scholar
33.Ball, MJ, Fisman, M, Hachinski, V, et al. A new definition of Alzeimer’s Disease: a hippocampal dementia. Lancet 1985; 1: 14–16.CrossRefGoogle Scholar